Ovarian cancer is the leading cause of gynaecological cancer death. The mortality rate of ovarian cancer could be greatly decreased if there were a screening test which was able to detect the disease at an early stage, resulting in an increased probability of cure. The most promising prospect for the early detection of ovarian cancer comes from the rapidly advancing field of clinical proteomics. An increasing number of reports on the potential clinical application of proteomics research for early detection as well as risk assessment and management of ovarian cancer are being published. Although the research is very promising, major technical challenges are still preventing new discoveries in ovarian cancer proteomics from being translated into clinical practice.